Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states

Hugo R. Arias, Dominik Feuerbach, Katarzyna M. Targowska-Duda, Krzysztof Jozwiak

Research output: Contribution to journalArticle

5 Scopus citations


The interaction of ibogaine analogs with nicotinic acetylcholine receptors (AChRs) in different conformational states was studied by functional and structural approaches. The results established that ibogaine analogs: (a) inhibit (±)-epibatidine-induced Ca 2+ influx in human embryonic muscle AChRs with the following potency sequence (IC 50 in μM): (±)-18-methylaminocoronaridine (5.9 ± 0.3) ∼ (±)-18-methoxycoronaridine (18-MC) (6.8 ± 0.8) > (-)-ibogaine (17 ± 3) ∼ (+)-catharanthine (20 ± 1) > (±)-albifloranine (46 ± 13), (b) bind to the [ 3H]TCP binding site with higher affinity when the Torpedo AChR is in the desensitized state compared to that in the resting state. Similar results were obtained using [ 3H]18-MC. These and docking results suggest a steric interaction between TCP and ibogaine analogs for the same site, (c) enhance [ 3H]cytisine binding to resting but not to desensitized AChRs, with desensitizing potencies (apparent EC 50) that correlate very well with the pK i values in the desensitized state, and (d) there are good bilinear correlations between the ligand molecular volumes and their affinities in the desensitized and resting states, with an optimal volume of ∼345 3 for the ibogaine site. These results indicate that the size of the binding sites for ibogaine analogs, located between the serine and nonpolar rings and shared with TCP, is an important structural feature for binding and for inducing desensitization.

Original languageEnglish
Pages (from-to)1330-1339
Number of pages10
JournalInternational Journal of Biochemistry and Cell Biology
Issue number9
StatePublished - 1 Sep 2011
Externally publishedYes



  • Conformational states
  • Ibogaine analogs
  • Molecular modeling
  • Nicotinic acetylcholine receptors
  • Noncompetitive antagonists
  • Structure-activity relationship

Cite this